Antabio raises €7.3M in series A

Antabio S.A.S. (Labege, France) said it raised €7.3 million ($8.6 million) in a series A round from iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion, and private individuals. Antabio is developing inhibitors of bacterial metalloenzymes that can be combined with antibiotics to break antibacterial resistance.

The company said it plans to begin clinical testing in 2019 of its lead candidate, an inhibitor of bacterial metallo beta-lactamases. Antabio plans to combine the candidate with a carbapenem antibiotic to treat hospitalized patients with Gram-negative bacterial infections...